Legal basis: Article 17 (1) of the Regulation (EU) No 596/2014 of the European Parliament and the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC
The Board of Directors of NESTMEDIC SA, a joint-stock company, with its registered office in Wrocław, announces that the current report submitted by the Current Report No. 3/2017 of July 3,2017, has been amended. The submitted confidential information should be worded as follows:
The Company announces that on July 3, 2017 the Company and Medicover Sp. z o.o., a limited company with its registered office in Warsaw signed a letter of intent.
The letter of intent opens negotiations on establishing the principles of co-operation between the parties and consequent conclusion of an agreement for providing services by the Company, based on the PREGNABIT system under the pilot agreement. The agreement for providing pilot services will be of commercial nature. The Parties agree that the services will be provided under this agreement until October 31, 2017, at the latest.
After the service provision under the pilot agreement has come to an end, depending on a positive assessment of the co-operation, the Parties will commence negotiations on establishing principles of future co-operation, with its aim being implementation of the PREGNABIT system in the Medicover medical centers.
This document does not create any legal obligations for any of the Parties.
The Company will inform on the coming stages of the deal, i.e. Concluding the pilot agreement and co-operation agreement in the following current reports.
